Jaguar health reports first quarter 2023 financial results

Net revenue decreased in q1 2023 versus q1 2022 net loss improved over the same period jaguar has agreed, as described below, not to issue additional equity securities before october 22, 2023 - by which point the company expects to have released top line data for the phase 3 ontarget trial completed and core near-term milestones: enrollment completed for phase 3 ontarget trial submission of investigational new drug (ind) application planned for q2 2023 to fda for crofelemer for microvillus inclusion disease reminder: jaguar to host investor webcast monday, may 15th at 8:30 a.m. eastern regarding first-quarter 2023 financials and company updates; click here to register for webcast san francisco, ca / accesswire / may 15, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported consolidated first-quarter 2023 financial results and provided company updates.
JAGX Ratings Summary
JAGX Quant Ranking